A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence: Moderation by Age of Onset and 5-Hydroxytryptamine Transporter-Linked Promoter Region Genotype
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Late-onset/low-vulnerability alcoholics (LOAs) appear to drink less when treated with a selective serotonin reuptake inhibitor than placebo, whereas early-onset/high-vulnerability alcoholics (EOAs) show the opposite effect. We conducted a 12-week, parallel-group, placebo-controlled trial of the efficacy of sertraline in alcohol dependence (AD). We compared the effects in LOAs versus EOAs and examined the moderating effects of a functional polymorphism in the serotonin transporter gene. Patients (N = 134, 80.6% male, 34.3% EOAs) with Diagnostic and Statistical Manual of Mental Disorders-IV AD received up to 200 mg of sertraline (n = 63) or placebo (n = 71) daily. We used urn randomization, and patients were genotyped for the tri-allelic 5-hydroxytryptamine transporter protein linked promoter region polymorphism. Planned analyses included main and interaction effects of medication group, age of onset (≤ 25 years vs >25 years), and genotype (L'/L' vs S' carriers) on drinking outcomes. Results showed that the moderating effect of age of onset on the response to sertraline was conditional on genotype. There were no main or interaction effects among S' allele carriers. However, in L' homozygotes, the effects of medication group varied by age of onset (P = 0.002). At the end of treatment, LOAs reported fewer drinking and heavy drinking days when treated with sertraline (P = 0.011), whereas EOAs had fewer drinking and heavy drinking days when treated with placebo (P < 0.001). The small cell sizes and high rate of attrition, particularly for L' homozygotes, render these findings preliminary and their replication in larger samples necessary. Because AD is common, particularly in medical settings, and selective serotonin reuptake inhibitors are widely prescribed by practitioners, these findings have potential public health significance and warrant further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 1×
“12% in 2005, with nearly three fourths of patients treated for a diagnosis other than depression.(52) More than 10% of adults from the National Comorbidity Survey Replication received antidepressant treatment in the year preceding the study, with nearly three quarters being treated by general medical providers, who we…”
BackgroundSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529 · cited 2×
“Variation in SLC6A4, which encodes the 5-HTT, could moderate the response to selective serotonin reuptake inhibitors (SSRIs).(16) A 44-bp repeat insertion polymorphism in the 5-HTT linked promoter region (5-HTTLPR) of SLC6A4 results in long (L) and short (S) alleles.”
BackgroundAn application of an urn model to the design of sequential controlled clinical trials.
Wei, L. J. (1978) · Journal of the American Statistical Association · doi:10.1080/01621459.1978.10480054 · Cited by 271
Mojtabai, R., & Olfson, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0704 · Cited by 185
Cited by
Antidepressants for the treatment of people with co-occurring depression and alcohol dependence
Agabio, R., Trogu, E., & Pani, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008581.pub2 · Cited by 131
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
Canadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715 · Cited by 74
“…observations regarding possible increases in alcohol use in certain individuals when prescribed serotonergic medications may have underlying genetic explanations 38 and are consistent with a range of nonhuman laboratory experiments 39 as well as randomized trials in other substance use disorders.”
BackgroundKenna, G. A., Zywiak, W. H., Swift, R. M., McGeary, J. E., Clifford, J. S., Shoaff, J. R., Fricchione, S., Brickley, M., Beaucage, K., Haass-Koffler, C. L., et al. (2014) · Alcohol · doi:10.1016/j.alcohol.2014.04.005 · Cited by 20
“However, recent clinical trials with ondansetron (Johnson et al., 2011) and sertraline (Kranzler et al., 2011) were not designed to investigate the possible moderating effect of the DRD4 alleles on the 5-HTTLPR alleles and treatment response.”
BackgroundResultInfluential
Metadata
- Authors
- Kranzler, H. R., Armeli, S., Tennen, H., Covault, J., Feinn, R., Arias, A. J., Pettinati, H., & Oncken, C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-02
- Volume
- 31
- Issue
- 1
- Pages
- 22-30
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W215685540
- Cited by
- 101
- References
- 9
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.